Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 27

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 27
---
 5.1. Approval of the compensation for the Board of Directors The board proposes to adjust the compensation for the Board of Directors, due to the transactions contemplated by the Merger, to a new maximum aggregate amount of CHF [●] for the fixed compensation of the Board of Directors. Furthermore the board proposes to set the grant of equity or equity linked instruments at a maximum aggregate amount of CHF [●] for the compensation of Board of Directors and the board proposes the participation in the purchase of a run-off insurance policy for the members of the Board of Directors, to be effective at the time of the merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the current term of office until the next Ordinary Shareholders Meeting. FOR AGAINST ABSTAIN 5.2. Approval of the compensation for the executive officers The board proposes to adjust the compensation for the Company’s executive officers, due to the transactions contemplated by the Merger, to a new maximum aggregate amount of CHF [●] for the fixed compensation and a new maximum aggregate amount of CHF [●] for the variable compensation of the Company’s executive officers. Furthermore the board proposes to set the grant of equity or equity linked instruments at a maximum aggregate amount of CHF [●] for the compensation of the Company’s executive officers and the board proposes the participation in the purchase of a run-off insurance policy for the Company’s executive officers, to be effective at the time of the merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the financial year 2025. FOR AGAINST ABSTAIN 6. Approval of Contingent Value Rights (CVR) Agreement on an advisory vote The board proposes to approve the CVR Agreement in the sense of an advisory vote. The company intends to work towards selling its existing R&D assets under development, excluding the DOXA asset. FOR AGAINST ABSTAIN 7. Approval of Option and RSU Conversion on and advisory vote The board proposes to approve the planned conversion of outstanding options and RSUs issued by Kadimastem into equivalent securities with identical rights in Company at the time of the completion of the transactions contemplated by the Merger Agreement in the sense of an advisory vote. FOR AGAINST ABSTAIN NLS PHARMACEUTICS LTD. Extraordinary Meeting of Shareholders [●], 2025 DETACH PROXY CARD HERE TO VOTE BY MAIL THIS PROXY IS SOLICITED